| Date | Title | Description |
| 09.04.2024 | Novo Nordisk to acquire Cardior Pharmaceuticals and strength... | Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals ... |
| 14.03.2024 | Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Milli... |
MUNICH, GERMANY, March 14, 2024 – Tubulis, a Fund+ portfolio company, today announced the successfu... |
| 30.08.2023 | Confo Therapeutics Appoints Dieter Weinand, Former CEO of Ba... | Ghent, Belgium – August 29, 2023 – Confo Therapeutics, a leader in the discovery of medicines target... |
| 15.06.2023 | Confo Therapeutics Enters into Research Collaboration for GP... | • Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled antibody discovery technol... |
| 05.06.2023 | Coave Therapeutics announces Positive 12-months Data from On... | – CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and e... |
| 05.06.2023 | ONA Therapeutics Announces the Appointment of Dr Pamela Klei... | • Leading medical oncologist and seasoned biotechnology executive with significant experience in dru... |
| 05.06.2023 | Minoryx gains FDA approval to initiate a Phase 3 clinical tr... | US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market whi... |
| 15.05.2023 | Indigo Appoints Dr. Arun Venkatasubramanian as Chief Technol... | Arun is an award-winning engineer who brings over 15 years’ experience in leading the design and dev... |
| 25.04.2023 | Minoryx presents positive interim results from NEXUS registr... | Initial evidence of disease stabilization was demonstrated for all patients using radiological, clin... |
| 20.04.2023 | Tubulis Announces Strategic License Agreement with Bristol M... | MUNICH, GERMANY, April 20, 2023 – Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced
that ... |
| 30.03.2023 | Confo Therapeutics Enters into Collaboration Agreement with ... | Ghent, Belgium – March 30, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeti... |
| 13.03.2023 | ExeVir Bio and VIB Announce Data on a New Therapy for Preven... | Ghent, Belgium, 13 March 2023: ExeVir Bio, a biotech company developing robust single domain antibod... |
| 02.03.2023 | Confo Therapeutics Announces Global Licensing Agreement with... | Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery of medicines targetin... |
| 30.01.2023 | Cellaion SA announces a total fundraising of EUR 23 million ... | Mont-Saint-Guibert, Belgium, 2023/01/13. Cellaïon is a biotechnology company based in Mont-St-Guiber... |
| 19.01.2023 | TargED Biopharmaceuticals announces the appointment of Erik ... | Utrecht, the Netherlands, January 19, 2023. TargED Biopharmaceuticals, a biotech spin-off of the Uni... |
| 09.01.2023 | Belgium: ExeVir lands European venture debt financing to dev... | Gent, 9 January 2022 – The European Investment Bank (EIB) and ExeVir BIO BV (ExeVir) have signed a €... |
| 27.12.2022 | Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief ... | Mont Saint-Guibert, Belgium – December 27, 2022 – Novadip Biosciences SA (“Novadip” or “the Company”... |
| 09.12.2022 | Novadip Biosciences SA Announces Positive Results from Phase... | Study results demonstrate NVD-003 has a favorable safety profile and convincing efficacy including r... |
| 10.11.2022 | Minoryx and Neuraxpharm announce a strategic alliance to pro... | The companies enter into a license agreement for the European rights to leriglitazone, currently und... |
| 04.11.2022 | Novadip Biosciences Raises Additional EUR 40 Million Bringin... | Funding will support development of next generation orthopedic products that provide accelerated hea... |
| 20.10.2022 | Coave Therapeutics Strengthens Board of Directors | Paris, France, October 20th, 2022 – Coave Therapeutics (‘Coave’), a biotech company leading the tran... |
| 20.10.2022 | ExeVir Bio Forges Ahead with Unique Next Generation COVID-19... | Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 varian... |
| 30.09.2022 | Indigo Diabetes Announces First Participant Enrolled in the ... | BELGIUM – Ghent, September 29, 2022 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering... |
| 26.09.2022 | Dr Jeanne Bolger to chair Board of Directors of Belgium-base... | |
| 26.09.2022 | AstriVax, an innovative vaccine platform company, establishe... | • Emmanuel Hanon, PhD, will chair the company’s scientific advisory board.
• Professor Peter Piot {M... |
| 20.09.2022 | Minoryx‘s Marketing Authorization Application for its lead c... | Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA ... |
| 20.09.2022 | Coave Therapeutics to Collaborate with World-Renowned Instit... | Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bor... |
| 25.08.2022 | KU Leuven spin-off AstriVax raises € 30 million to build vac... | KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform |
| 17.08.2022 | Immunic Receives Notice of Allowance for Composition-of-Matt... | Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-8... |
| 27.07.2022 | Cardior Announces First Patient Dosed in Phase 2 Study Evalu... | Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding ... |
| 07.07.2022 | Immunic, Inc. Strengthens Its Board of Directors with the Ap... | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén |
| 31.05.2022 | Minoryx raises €51 million to support Marketing Authorizatio... | Funds will support the marketing authorization review process for male patients with AMN and launch ... |
| 05.05.2022 | Immunic Announces Start of Patient Cohorts in Its Phase 1 Cl... | Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Diseas... |
| 03.05.2022 | Tubulis Closes €60 Million Series B Financing to Accelerate ... | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth ... |
| 29.03.2022 | Cellaïon announces update to its Board of Directors: Dr. Fou... | Cellaïon announces update to its Board of Directors: Dr. Fouzia LAGHRISSI-THODE joins the biotech as... |
| 10.03.2022 | Confo Therapeutics Doses First Subjects in Phase 1 Clinical ... | Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of ... |
| 24.02.2022 | Immunic, Inc. Reports Year End 2021 Financial Results and Hi... | – Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relaps... |
| 22.02.2022 | TargED Biopharmaceuticals raises EUR 39 Million in Series A ... | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thromb... |
| 03.02.2022 | eTheRNA immunotherapies and Ghent University Announce mRNA D... | Partnership Press Release |
| 13.01.2022 | Epics Therapeutics Initiates First-in-Human Studies with EP2... | - |
| 16.12.2021 | Confo Therapeutics Expands Patent Estate for ConfoBody®-base... | Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform |
| 14.12.2021 | Immunic, Inc. Publishes Positive Results from the Single and... | – Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose ... |
| 10.12.2021 | Immunic, Inc. Announces Enrollment of the First Patient in i... | NEW YORK, Dec. 9, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutic... |
| 02.12.2021 | ONA Therapeutics Appoints Dr Michel Detheux as Independent C... | ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors |
| 30.11.2021 | Confo Therapeutics Enters Collaborative Agreement with Regen... | Confo Therapeutics Enters Collaborative Agreement with Regeneron |
| 22.11.2021 | Immunic, Inc. Announces Enrollment of First Patient in its P... | NEW YORK, Nov. 18, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceuti... |
| 04.11.2021 | Immunic, Inc. Reports Third Quarter 2021 Financial Results a... | – Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis – |
| 03.11.2021 | Additional data from Minoryx’s Phase 2/3 ADVANCE clinical tr... | Mataró, Barcelona, Spain, November 3, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech ... |
| 28.10.2021 | Immunic, Inc. Announces Completion of Enrollment of its Phas... | |
| 28.10.2021 | Novadip Biosciences announces EUR 19 million Series B financ... | Novadip Biosciences announces EUR 19 million Series B financing backed by international investors |
| 22.10.2021 | Egle Therapeutics raises 40 million € Series A to develop Fi... | Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Clas... |
| 21.10.2021 | ONA Therapeutics Strengthens Scientific Leadership Team | ONA Therapeutics Strengthens Scientific Leadership Team |
| 19.10.2021 | Fund+ on LN24 | Very proud of FundPlus on LN24 in #successstories, #lifesciences #biotechs #investmentopportunities ... |
| 15.10.2021 | Immunic, Inc. Appoints Patrick Walsh as Chief Business Offic... | NEW YORK, Oct. 14, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceuti... |
| 12.10.2021 | Coave Therapeutics appoints Olivier Danos and Frederic Chere... | Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Boa... |
| 01.10.2021 | Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER ... | NEW YORK, Sept. 30, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceut... |
| 22.09.2021 | Immunic and the University Medical Center Goettingen Sign Li... | Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination... |
| 16.09.2021 | Coave Therapeutics and Théa Open Innovation sign exclusive l... | Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commerciali... |
| 01.09.2021 | ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinic... | ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral ... |
| 25.08.2021 | Cardior Raises €64 M Series B to Advance Clinical Pipeline o... | Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Dise... |
| 18.08.2021 | ExeVir announces first subjects dosed in Phase I clinical st... | ExeVir announces first subjects dosed |
| 22.07.2021 | Coave Therapeutics Closes €33 million ($39 million) Series B... | Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy P... |
| 20.07.2021 | Immunic, Inc. Announces Closing of $45.0 Million Public Offe... | Immunic, Inc. Announces Closing of $45.0 Million Public Offering |
| 15.07.2021 | ExeVir and Mithra announce manufacturing collaboration for i... | ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments |
| 15.07.2021 | eTheRNA immunotherapies and Ghent University Announce mRNA D... | eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreem... |
| 13.07.2021 | ExeVir’s COVID-19 antibody candidate neutralizes coronavirus... | ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern |
| 01.07.2021 | Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase... | Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting... |
| 29.06.2021 | eTheRNA immunotherapies and Quantoom Biosciences Announce a ... | eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Developm... |